Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis

被引：0
|
作者：
Pui San Tan
Pedro Aguiar
Benjamin Haaland
Gilberto Lopes
机构：
[1] University of Oxford,Nuffield Department of Primary Care Health Sciences
[2] Clinical Oncology Sector,Population Health Sciences and Huntsman Cancer Institute
[3] Faculdade de Medicina do ABC,Sylvester Comprehensive Cancer Center
[4] University of Utah,undefined
[5] University of Miami,undefined
来源：
Prostate Cancer and Prostatic Diseases | 2018年 / 21卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：516 / 523
页数：7
相关论文
共 50 条
  • [21] Treatment patterns for metastatic hormone-sensitive prostate cancer (mHSPC) progressing after up-front docetaxel in combination with androgen deprivation therapy (D-ADT).
    Barata, Pedro C.
    Emamekhoo, Hamid
    Mendiratta, Prateek
    Gopalakrishnan, Dharmesh
    Koshkin, Vadim S.
    Tyler, Allison Janine
    Ornstein, Moshe Chaim
    Grivas, Petros
    Gilligan, Timothy D.
    Rini, Brian I.
    Kyriakopoulos, Christos
    Garcia, Jorge A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [22] Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer
    Sathianathen, Niranjan J.
    Oestreich, Makinna C.
    Brown, Sarah Jane
    Gupta, Shilpa
    Konety, Badrinath R.
    Dahm, Philipp
    Kunath, Frank
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2020, (12):
  • [23] Use of abiraterone for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
    Cathomas, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 130 - 130
  • [24] Cost-effectiveness analysis of additional abiraterone for hormone-sensitive metastatic prostatic cancer treated with androgen deprivation therapy (ADT)
    Chiang, C. L.
    Choi, H.
    Mui, W. H.
    So, T. H.
    ANNALS OF ONCOLOGY, 2017, 28 : 80 - 80
  • [25] ARASENS Trial: Should darolutamide now be added to androgen-deprivation therapy and docetaxel in patients with metastatic, hormone-sensitive prostate cancer?
    Kumar, Naveen
    INDIAN JOURNAL OF UROLOGY, 2022, 38 (03) : 238 - 239
  • [26] Early Docetaxel and Androgen Deprivation in the Treatment of Metastatic, Hormone-sensitive Prostate Cancer
    Tassinari, Davide
    Tamburini, Emiliano
    Gianni, Lorenzo
    Drudi, Fabrizio
    Fantini, Manuela
    Santelmo, Carlotta
    Stocchi, Lucia
    Montanari, Francesco
    Sartori, Sergio
    REVIEWS ON RECENT CLINICAL TRIALS, 2016, 11 (04) : 317 - 323
  • [27] Efficacy and safety of darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) by metastatic burden: Subgroup analyses of ARASENS
    Tombal, B.
    Saad, F.
    Fizazi, K.
    Sternberg, C. N.
    Crawford, E. D.
    Gratzke, C.
    Grabbert, M.
    Vilaseca, A.
    Shore, N.
    Kopyltsov, E.
    Boegemann, M.
    Kapur, S.
    Srinivasan, S.
    Verholen, F.
    Kuss, I.
    Joensuu, H.
    Smith, M. R.
    Hussain, M.
    EUROPEAN UROLOGY, 2023, 83
  • [28] A retrospective review of the benefits vs. safety implications of prednisolone during docetaxel chemotherapy alongside androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC).
    Jameson, Molly
    Barker, Claire
    King, Jennifer
    Liang, Hui-Wen
    Carey, Charles
    Cripps, Nicole
    Jameson, Daisy
    Patel, Kamlesh
    Robinson, Andrew
    Hudson, Andrew
    Song, Yee Pei
    Conroy, Ruth
    Serra, Maria
    Choudhury, Ananya
    Logue, John
    Wylie, James
    Tran, Anna
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [29] Androgen-deprivation therapy plus chemotherapy in metastatic hormone-sensitive prostate cancer. A systematic review and meta-analysis of randomized clinical trials
    Ramos-Esquivel, Allan
    Fernandez, Cristina
    Zeledon, Zenen
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2016, 34 (08) : 335.e9 - 335.e19
  • [30] Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective
    Zheng, H. R.
    Wen, F.
    Wu, Y. F.
    Wheeler, J. R. C.
    Li, Q.
    EUROPEAN JOURNAL OF CANCER CARE, 2017, 26 (06)
12345